Clinical Trials Logo

Kidney Neoplasms clinical trials

View clinical trials related to Kidney Neoplasms.

Filter by:

NCT ID: NCT00293501 Active, not recruiting - Kidney Cancer Clinical Trials

Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Start date: December 2005
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Tinzaparin may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects of tinzaparin and to see how well it works in treating patients with metastatic kidney cancer that cannot be removed by surgery.

NCT ID: NCT00093522 Active, not recruiting - Kidney Cancer Clinical Trials

Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer

Start date: August 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with fludarabine may kill more tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy and fludarabine to see how well they work compared to vaccine therapy alone in treating patients with stage IV kidney cancer.

NCT ID: NCT00080977 Active, not recruiting - Kidney Cancer Clinical Trials

High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2

Start date: June 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill renal cell carcinoma (kidney cancer) cells. PURPOSE: This phase II trial is studying how well high-dose intravenous interleukin-2 works in treating patients with metastatic renal cell carcinoma that has not responded to previous low-dose intravenous or subcutaneous interleukin-2.

NCT ID: NCT00039169 Active, not recruiting - Kidney Cancer Clinical Trials

BAY 59-8862 in Treating Patients With Advanced Kidney Cancer

Start date: December 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have advanced kidney cancer.

NCT ID: NCT00030888 Active, not recruiting - Kidney Cancer Clinical Trials

UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer

Start date: December 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of UCN-01 in treating patients who have unresectable stage III or stage IV kidney cancer.

NCT ID: NCT00027664 Active, not recruiting - Kidney Cancer Clinical Trials

Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer

Start date: February 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. It is not yet known if interferon alfa is more effective with or without thalidomide in treating metastatic kidney cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of interferon alfa with or without thalidomide in treating patients who have metastatic kidney cancer.

NCT ID: NCT00024388 Active, not recruiting - Kidney Cancer Clinical Trials

Chemotherapy in Treating Patients With Metastatic Kidney Cancer

Start date: April 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have locally advanced, metastatic, or unresectable kidney cancer.

NCT ID: NCT00005958 Active, not recruiting - Bladder Cancer Clinical Trials

Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer

Start date: October 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with gemcitabine and docetaxel plus filgrastim in treating patients who have locally recurrent or advanced urothelium cancer.

NCT ID: NCT00005038 Active, not recruiting - Kidney Cancer Clinical Trials

Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer

Start date: June 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. Histamine dihydrochloride may prolong survival and improve quality of life in patients with metastatic kidney cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of interleukin-2 with or without histamine dihydrochloride in treating patients who have metastatic kidney cancer.

NCT ID: NCT00003664 Active, not recruiting - Kidney Cancer Clinical Trials

Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically

Start date: October 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with biological therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and biological therapy in treating patients with kidney cancer that is metastatic or cannot be removed surgically.